{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:21:43Z","timestamp":1790144503860,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.036","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:42:16Z","timestamp":1682437336000},"page":"3387-3398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martinon-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Szenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Carmona-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Poder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-1046","authenticated-orcid":false,"given":"Ron","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7562-7228","authenticated-orcid":false,"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Chantale","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4823-1874","authenticated-orcid":false,"given":"Robert","family":"Lupinacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"McFetridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-466X","authenticated-orcid":false,"given":"Richard T.","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Gerrits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Banniettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-7037","authenticated-orcid":false,"given":"Luwy","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Bickham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2023.04.036_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a010215","article-title":"The pneumococcus: epidemiology, microbiology, and pathogenesis","volume":"3","author":"Henriques-Normark","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.04.036_b0010","first-page":"1135","article-title":"Prevalence of invasive Streptococcus pneumoniae infections among Iranian children: a systematic review and meta-analysis","volume":"50","author":"Avarvand","year":"2021","journal-title":"Iran J Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2023.04.036_b0015","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1017\/S0950268813002744","article-title":"Incidence and clinical presentation of acute otitis media in children aged <6 years in European medical practices","volume":"142","author":"Liese","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2023.04.036_b0020","unstructured":"European Centre for Disease Prevention and Control. Invasive Pneumococcal Disease Annual Epidemiological Report for 2017; 2019. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-pneumococcal-disease.pdf [Accessed March 22, 2022]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0025","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report: Streptococcus pneumoniae, 2019; 2019. Available from: https:\/\/www.cdc.gov\/abcs\/downloads\/SPN_Surveillance_Report_2019.pdf [Accessed March 23, 2022]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0030","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fimmu.2018.01366","article-title":"Streptococcus pneumoniae\u2019s virulence and host immunity: aging, diagnostics, and prevention","volume":"9","author":"Brooks","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.036_b0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00018-12","article-title":"Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines","volume":"25","author":"Tan","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2023.04.036_b0040","unstructured":"G. B. D. Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18(11):1191\u2013210."},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.036_b0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/INF.0000000000000484","article-title":"Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012","volume":"34","author":"von Mollendorf","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.036_b0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jama.1995.03520350041026","article-title":"Risk factors for primary invasive pneumococcal disease among children in Finland","volume":"273","author":"Takala","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.036_b0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vaccine.2023.04.036_b0060","unstructured":"European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases; 2019. Available from: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx [Accessed September 22, 2022]."},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.036_b0065","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.036_b0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2023.04.036_b0075","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.036_b0080","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cix115","article-title":"Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era","volume":"64","author":"Olarte","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2023.04.036_b0085","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jama.295.14.1668","article-title":"Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine","volume":"295","author":"Poehling","year":"2006","journal-title":"JAMA"},{"issue":"45","key":"10.1016\/j.vaccine.2023.04.036_b0090","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.vaccine.2020.08.068","article-title":"Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis","volume":"38","author":"Chapman","year":"2020","journal-title":"Vaccine"},{"issue":"35 Pt B","key":"10.1016\/j.vaccine.2023.04.036_b0095","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1016\/j.vaccine.2017.07.010","article-title":"Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure","volume":"35","author":"Camilli","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.036_b0100","unstructured":"Corcoran M, Mereckiene J, Cotter S, Murchan S, Cunney R, Humphreys H. The threat posed by increased non-PCV13 serotypes in children \u2013 results from Irish surveillance data from 2007-08 to 2018-19. Presented at: The International Symposium on Pneumococci and Pneumococcal Diseases, Virtual; 2020."},{"issue":"27","key":"10.1016\/j.vaccine.2023.04.036_b0105","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","article-title":"Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance","volume":"32","author":"Ben-Shimol","year":"2014","journal-title":"Vaccine"},{"issue":"12 Suppl 2","key":"10.1016\/j.vaccine.2023.04.036_b0110","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1093\/infdis\/jiab217","article-title":"The global landscape of pediatric bacterial meningitis data reported to the World Health Organization-coordinated invasive bacterial vaccine-preventable disease surveillance network, 2014\u20132019","volume":"224","author":"Nakamura","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.036_b0115","unstructured":"Food and Drug Administration. PREVNAR 13 Prescribing information; 2017. Available from: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert------Prevnar-13.pdf [Accessed October 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0120","unstructured":"Food and Drug Administration. VAXNEUVANCE Prescribing information; 2022 Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_pi.pdf [Accessed October 20, 2022]."},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.036_b0125","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.036_b0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.036_b0135","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14760584.2019.1688149","article-title":"Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD)","volume":"18","author":"Tin Tin Htar","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.036_b0140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.036_b0145","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases - invasive pneumococcal disease, confirmed cases, age below 1 (2017); 2023. Available from: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx [Accessed January 2023]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0150","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Disease - invasive pneumococcal disease, confirmed cases, age 1-4 (2017); 2023. Available from: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx [Accessed January 2023]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0155","unstructured":"United States Food and Drug Administration. VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) Prescribing information; 2021. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaxneuvance [Accessed August 10, 2022]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0160","unstructured":"Merck & Co., Inc. Vaxneuvance Summary of Product Characteristics; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxneuvance-epar-product-information_en.pdf [Accessed November 29, 2022]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0165","unstructured":"Government of Canada. Pneumococcal vaccine: Canadian immunization guide; 2022. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-16-pneumococcal-vaccine.html#a4 [Accessed June 07, 2022]."},{"key":"10.1016\/j.vaccine.2023.04.036_b0170","unstructured":"Health Canada. VAXNEUVANCE\u00ae Product monograph; 2022. Available from: https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2022\/06\/VAXNEUVANCE-PM_E.pdf [Accessed August 26, 2022]."},{"issue":"8","key":"10.1016\/j.vaccine.2023.04.036_b0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/INF.0000000000002765","article-title":"A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants","volume":"39","author":"Platt","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.036_b0180","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/21645515.2019.1568159","article-title":"A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"15","author":"Rupp","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.036_b0185","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0000000000000516","article-title":"Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine","volume":"34","author":"Sobanjo-ter Meulen","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.04.036_b0190","doi-asserted-by":"crossref","unstructured":"Benfield T, R\u00e4met M, Valentini P, Sepp\u00e4 I, Musey L, Bickham K, et al. Phase 3 study of safety, tolerability and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants (PNEU-PED-EU-2). Eudopean Society for Paediatric Infectious Diseases (ESPID), Athens, Greece; 2022.","DOI":"10.1016\/j.vaccine.2023.02.041"},{"key":"10.1016\/j.vaccine.2023.04.036_b0195","unstructured":"Musey L, Quinn C, Wiedmann R, Papa M, Shou Q, Dagan R, et al. A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease (PNEU\u2013SICKLE). Presented at: Pediatric Academic Societies (PAS), Denver, CO, USA; 2022."},{"issue":"19","key":"10.1016\/j.vaccine.2023.04.036_b0200","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/bio-2020-0023","article-title":"Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"issue":"14","key":"10.1016\/j.vaccine.2023.04.036_b0205","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.4155\/bio-2020-0024","article-title":"Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.036_b0210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2023.04.036_b0215","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. WHO TRS N\u00b0977, Annex 3; 2013. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/vaccine-standardization\/pneumococcus\/trs_977_annex_3.pdf?sfvrsn=344f81e_3&download=true [Accessed October 31, 2022]."},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.036_b0220","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1128\/IAI.00739-10","article-title":"Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae","volume":"78","author":"Melin","year":"2010","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.036_b0225","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2013.228052","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial","volume":"310","author":"Spijkerman","year":"2013","journal-title":"JAMA"},{"issue":"29","key":"10.1016\/j.vaccine.2023.04.036_b0230","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1016\/j.vaccine.2021.05.089","article-title":"Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children","volume":"39","author":"Kaur","year":"2021","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.036_b0235","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0022-3476(66)80444-4","article-title":"Serum immunoglobulin measurement during the first year of life and in immunoglobulin-deficiency states","volume":"68","author":"Fulginiti","year":"1966","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.vaccine.2023.04.036_b0240","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3346\/jkms.2016.31.6.950","article-title":"Impact of IgM antibodies on cross-protection against pneumococcal serogroups 6 and 19 after immunization with 7-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Cho","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.036_b0245","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.036_b0250","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1542\/peds.2014-2941","article-title":"13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants","volume":"135","author":"Martinon-Torres","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.04.036_b0255","unstructured":"European Centre for Disease Prevention and Control. Pneumococcal Disease: Recommended vaccinations; 2022. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1 [Accessed March 29, 2022]."}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2024.126628","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:35:55Z","timestamp":1740375355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":51,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23004280"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.036","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd All rights reserved.","name":"copyright","label":"Copyright"}]}}